Therapeutics

Breaking News

On February 14, Merck announced that it will stop testing the BACE inhibitor verubecestat in people with mild to moderate AD. An external data-monitoring committee concluded there was virtually no chance of a positive effect in the trial, called EPOCH. Merck’s APECS trial of verubecestat in prodromal AD will continue.

This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at therapeutics@alzforum.org.

Tools

Back to the Top
Search Therapeutics

AD Target / Therapy Types

The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.

Discussion

Recent Comments

  1. John (Wes) Ashford on Verubecestat
  2. Kristina Capiak on Anavex 2-73

Further Reading

News

  1. Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
  2. After Solanezumab: Where Should Alzheimer’s Research Go?
  3. Solanezumab: Did Aβ ‘Reflux’ From Blood Confound Target Engagement in CSF?
  4. Antisense Oligos Tango with Tau Transcripts to Reverse Tauopathy

Webinars

  1. Suzanne Hendrix on Constructing Composites for Trials in Early Alzheimer’s
  2. Computational Modeling—Will it Rescue AD Clinical Trials?
  3. Resolving Controversies on the Path to AD Therapeutics
  4. Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD

Other Resources

ADDF ACCESS is a program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases.

Patient Resources